

# Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies

Manuela Casula <sup>1,2</sup>, Federica Galimberti <sup>2</sup>, Marica Iommi <sup>3</sup>, Elena Olmastroni <sup>1,\*</sup>, Simona Rosa <sup>4</sup>, Mattia Altini <sup>5</sup>, Alberico L. Catapano <sup>1,2</sup>, Elena Tragni <sup>1</sup> and Elisabetta Poluzzi <sup>3</sup>

<sup>1</sup> Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy

<sup>2</sup> IRCCS MultiMedica, Via Milanese 300, Sesto S. Giovanni, 20099 Milan, Italy

<sup>3</sup> Department of Medical and Surgical Sciences-Pharmacology Unit, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy

<sup>4</sup> Department of Biomedical and Neuromotor Sciences-Hygiene and Biostatistics Unit, University of Bologna, Via San Giacomo, 40126 Bologna, Italy


<sup>5</sup> Romagna Local Health Authority, Emilia-Romagna Region, Via A. De Gasperi 8, 48121 Ravenna, Italy

\* Correspondence: elena.olmastroni@unimi.it

**Table S1.** List of ATC codes for each cohort.

<b>Chronic Treatment</b>	<b>ATC Codes</b>
<b>Lipid-lowering drugs</b>	<p><b>Class 1 (statins):</b> C10AA, C10BA02, C10BA05, C10BA06</p> <p><b>Class 2 (PCSK9 inhibitors):</b> C10AX13, C10AX14</p> <p><b>Class 3 (ezetimibe):</b> C10AX09, C10BA02, C10BA05, C10BA06</p>
<b>Antidiabetics</b>	<p><b>Class 1 (biguanides):</b> A10BA, A10BD02, A10BD05, A10BD07, A10BD08, A10BD10, A10BD11, A10BD13, A10BD15, A10BD16, A10BD20, A10BD23</p> <p><b>Class 2 (sulfonylureas):</b> A10BB, A10BD02, A10BD06</p> <p><b>Class 3 (sulfonamides):</b> A10BC</p> <p><b>Class 4 (alpha glucosidase inhibitors):</b> A10BF</p> <p><b>Class 5 (thiazolidinediones):</b> A10BG, A10BD05, A10BD06, A10BD09</p> <p><b>Class 6 (dipeptidyl peptidase 4 (DPP-4) inhibitors):</b> A10BH, A10BD07, A10BD08, A10BD09, A10BD10, A10BD11, A10BD13, A10BD19, A10BD21</p> <p><b>Class 7 (glucagon-like peptide-1 (GLP-1) analogues):</b> A10BJ</p> <p><b>Class 8 (sodium-glucose co-transporter 2 (SGLT2) inhibitors):</b> A10BK, A10BD15, A10BD16, A10BD19, A10BD20, A10BD21, A10BD23</p> <p><b>Class 9 (other blood glucose lowering drugs, excl. insulins):</b> A10BX</p>
<b>Antihypertensives</b>	<p><b>Class 1 (antiadrenergic agents):</b> C02</p> <p><b>Class 2 (diuretics):</b> C03, C07BB, C07CB, C09BA, C09BX01, C09DA, C09XA52</p> <p><b>Class 3 (beta blocking agents):</b> C07, C07BB, C07CB, C09BX02</p> <p><b>Class 4 (calcium channel blockers):</b> C08, C09BB, C09BX01, C09DB</p> <p><b>Class 5 (agents acting on the renin-angiotensin system):</b> C09, C09BA, C09BB, C09BX01, C09BX02, C09DA, C09DB, C09XA52</p>

**Figure S1.** Example of PDC calculation for an individual with two concurrent therapeutic classes within the same chronic therapy.




Days of follow-up: 240

Days covered: 30 + 30 + 60 + 7 + 30 + 60 = 217


Proportion of days covered (PDC):  $\frac{217}{240} = 0.90$

Figure S2. Timeline of the study.




**Figure S3.** Difference in dispensed packages per 1000 patients between study and control periods by sex.


(A) Lipid-lowering drugs



(B) Antidiabetic drugs




(C) Antihypertensive drugs




**Figure S4.** Difference in dispensed packages per 1000 patients between study and control periods by age groups.


(A) Lipid-lowering drugs



(B) Antidiabetic drugs




(C) Antihypertensive drugs



**Figure S5.** Fifty two-week trends in chronic therapies dispensing in the population by metropolitan areas (those in dark blue represent areas with more COVID-19 cases recorded in 2020, while in light blue those with fewer cases)


(A) Lipid-lowering drugs



	$\Delta P1$	$\Delta P2$	$\Delta P3$	$\Delta P4$	$\Delta P5$	$\Delta P6$
Dark Blue	2.52%	2.81%	-7.03%	-3.04%	1.09%	-7.49%
Medium Blue	2.39%	4.86%	-9.68%	-1.52%	0.50%	-6.66%
Light Blue	1.22%	5.86%	-7.62%	-1.85%	2.35%	-3.79%

(B) Antidiabetic drugs


Antidiabetic drugs - delta in dispensed packages (2020 vs 2019)



	$\Delta P1$	$\Delta P2$	$\Delta P3$	$\Delta P4$	$\Delta P5$	$\Delta P6$
Dark Blue	0.32%	0.06%	-11.74%	-7.41%	-3.56%	-11.18%
Medium Blue	-0.60%	3.02%	-12.98%	-5.96%	-3.01%	-10.97%
Light Blue	-0.60%	4.95%	-10.81%	-6.48%	-2.94%	-8.22%

### (C) Antihypertensive drugs

Antihypertensive drugs - delta in dispensed packages (2020 vs 2019)



	$\Delta P1$	$\Delta P2$	$\Delta P3$	$\Delta P4$	$\Delta P5$	$\Delta P6$
	-0.65%	-1.30%	-9.95%	-5.73%	-2.45%	-10.31%
	-0.83%	1.87%	-11.45%	-4.39%	-2.59%	-9.25%
	-1.46%	2.28%	-9.54%	-4.57%	-1.57%	-6.84%